Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Oncology · Esophageal and Esophagogastric Junction Adenocarcinoma

Pathology & Biomarkers: Decoding Your Report

At a Glance

A pathology report for esophageal adenocarcinoma details the cancer's stage and specific biomarkers like HER2, PD-L1, MSI-H, and CLDN18.2. These specific protein and genetic markers are crucial for determining if you are eligible for targeted therapies and immunotherapies.

Your pathology report is the “blueprint” of your cancer. It contains the microscopic details that tell your medical team exactly what they are fighting [1]. While the language can be dense, knowing which parts to look for will help you ensure you are receiving modern, personalized care—treatment tailored specifically to your tumor’s unique genetic and protein makeup [2][3].

The Basics: TNM Staging

Every report will include the TNM Stage, which is the universal language of cancer severity [4]:

  • T (Tumor Depth): How far the cancer has grown into the layers of the esophageal or stomach wall [4].
  • N (Nodes): Whether the cancer has spread to nearby lymph nodes, and if so, how many [5]. Guidelines suggest that at least 15 lymph nodes should be examined during surgery for the most accurate staging [6].
  • M (Metastasis): Whether the cancer has been found in distant organs like the liver or lungs [7].

Mandatory Biomarkers for Advanced Disease

If your cancer is advanced or metastatic, testing for specific biomarkers is not just recommended—it is mandatory for deciding your treatment [2][8]. These markers act like “locks” that can be opened by specific “key” drugs:

  1. HER2 Status: This protein can promote rapid cancer growth. If your tumor is “HER2-positive,” you can receive drugs like trastuzumab that specifically target this protein [9][8].
  2. PD-L1 (CPS Score): PD-L1 is a protein that helps cancer hide from your immune system. Your report should show a Combined Positive Score (CPS) [10]. A higher score (often ≥5\geq 5 or ≥10\geq 10) usually means a better chance of responding to immunotherapy [11][12].
  3. MSI-H / dMMR: This tells doctors if your tumor has a specific type of genetic instability. Tumors that are MSI-High (MSI-H) often respond very well to immunotherapy and may even allow for different chemotherapy choices [13][14].

A New Frontier: CLDN18.2

A newly emerging and highly important marker is CLDN18.2 [15]. Research has shown that a new drug, zolbetuximab, can significantly improve survival for patients whose tumors have high levels of this protein [16][17]. For the best chance of success, at least 75% of the cancer cells must show moderate-to-strong levels of CLDN18.2 on the report [18][19].

Your ‘Completeness Checklist’

When you look at your report, make sure these items are present or have been ordered:

  • [ ] Histologic Grade: How aggressive the cells look (G1, G2, or G3) [20].
  • [ ] Siewert Classification: For tumors at the junction (Type I, II, or III) [21].
  • [ ] HER2 Testing: (By IHC or FISH) [9].
  • [ ] PD-L1 CPS Score: (Specifically a CPS number, not just “positive”) [10].
  • [ ] MSI/dMMR Status: [14].
  • [ ] CLDN18.2 Status: (Especially if the cancer is HER2-negative) [15].
  • [ ] Tumor Regression Grade (TRG): (If you had treatment before surgery, this shows how much of the cancer died) [22].

If any of these are missing, it is a perfect opportunity to ask your oncologist: “Can we order these tests to make sure we are not missing any targeted treatment options?” [2].

Common questions in this guide

What does a PD-L1 Combined Positive Score (CPS) mean?
PD-L1 is a protein that helps cancer cells hide from your immune system. A higher Combined Positive Score (CPS) usually indicates that your tumor has a better chance of responding to immunotherapy treatments.
Why is HER2 testing important for esophageal cancer?
HER2 is a protein that can cause cancer cells to grow rapidly. If your pathology report shows your tumor is HER2-positive, you may be eligible for targeted therapies like trastuzumab.
What is the CLDN18.2 biomarker?
CLDN18.2 is a newer biomarker found in some esophageal and stomach cancers. If at least 75% of your cancer cells show high levels of this protein, you may benefit from specific new targeted therapies.
What does MSI-High or dMMR mean on my report?
MSI-High or dMMR indicates your tumor has a specific type of genetic instability. Tumors with this marker often respond very well to immunotherapy and it may help your doctor choose the best chemotherapy options.
What is a Tumor Regression Grade (TRG)?
Tumor Regression Grade measures how much of the cancer was destroyed by treatments you received before surgery. It helps your medical team understand how well your initial therapy worked.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my PD-L1 result reported as a 'Combined Positive Score' (CPS)? What is that specific number?
  2. 2.If my HER2 IHC was '2+,' was a follow-up FISH or ISH test performed to confirm my status?
  3. 3.Has my tumor been tested for CLDN18.2? If so, does it meet the '75% staining' threshold for the latest targeted therapies?
  4. 4.How does my tumor's 'Microsatellite Instability' (MSI) status change the type of chemotherapy or immunotherapy you are recommending?
  5. 5.On my surgical pathology report, what was the 'Tumor Regression Grade' (TRG), and what does it tell us about how my cancer responded to the initial treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    A novel framework for esophageal cancer grading: combining CT imaging, radiomics, reproducibility, and deep learning insights.

    Alsallal M, Ahmed HH, Kareem RA, et al.

    BMC gastroenterology 2025; (25(1)):356 doi:10.1186/s12876-025-03952-6.

    PMID: 40348987
  2. 2

    Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

    Ajani JA, D'Amico TA, Bentrem DJ, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2023; (21(4)):393-422 doi:10.6004/jnccn.2023.0019.

    PMID: 37015332
  3. 3

    Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma.

    Fick CN, Dunne EG, Sihag S, et al.

    The Annals of thoracic surgery 2024; (118(1)):130-140 doi:10.1016/j.athoracsur.2024.02.021.

    PMID: 38408631
  4. 4

    Comparison Between Size and Stage of Preoperative Tumor Defined by Preoperative Magnetic Resonance Imaging and Postoperative Specimens After Radical Resection of Esophageal Cancer.

    Gao Z, Hua B, Ge X, et al.

    Technology in cancer research & treatment 2019; (18()):1533033819876263 doi:10.1177/1533033819876263.

    PMID: 31551000
  5. 5

    Tumor location is an independent prognostic factor of esophageal adenocarcinoma based on the eighth edition of TNM staging system in Chinese patients.

    Deng HY, Zheng X, Alai G, et al.

    Annals of translational medicine 2019; (7(16)):365 doi:10.21037/atm.2019.01.84.

    PMID: 31555679
  6. 6

    Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus minimally invasive esophagectomy for resectable esophageal adenocarcinoma, a randomized controlled trial (ROBOT-2 trial).

    Tagkalos E, van der Sluis PC, Berlth F, et al.

    BMC cancer 2021; (21(1)):1060 doi:10.1186/s12885-021-08780-x.

    PMID: 34565343
  7. 7

    Esophageal cancer - the utility of PET/CT in staging prior to chemoradiation.

    Deja A, Włodarczyk M

    Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology 2023; (28(5)):608-611 doi:10.5603/rpor.96869.

    PMID: 38179288
  8. 8

    Selected updates in molecular and genomic pathology of esophageal cancer.

    Liu Y, Zhao L, Xue L, Hou Y

    Annals of the New York Academy of Sciences 2020; (1482(1)):225-235 doi:10.1111/nyas.14527.

    PMID: 33215736
  9. 9

    Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.

    Shah MA, Kennedy EB, Alarcon-Rozas AE, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(7)):1470-1491 doi:10.1200/JCO.22.02331.

    PMID: 36603169
  10. 10

    Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.

    Yamashita K, Iwatsuki M, Harada K, et al.

    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2020; (23(1)):95-104 doi:10.1007/s10120-019-00999-9.

    PMID: 31451991
  11. 11

    PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase III randomized trials.

    Formica V, Morelli C, Fornaro L, et al.

    ESMO open 2024; (9(11)):103967 doi:10.1016/j.esmoop.2024.103967.

    PMID: 39541621
  12. 12

    The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis.

    Li JB, Lai MY, Lin ZC, et al.

    Cancer immunology, immunotherapy : CII 2024; (73(7)):132 doi:10.1007/s00262-024-03726-1.

    PMID: 38753055
  13. 13

    Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing.

    Lavacchi D, Fancelli S, Buttitta E, et al.

    International journal of molecular sciences 2023; (24(5)) doi:10.3390/ijms24054877.

    PMID: 36902306
  14. 14

    Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives.

    Sato Y, Okamoto K, Kawano Y, et al.

    Journal of clinical medicine 2023; (12(14)) doi:10.3390/jcm12144646.

    PMID: 37510761
  15. 15

    Clinical Pharmacology Profile of the Claudin 18.2 Antibody Zolbetuximab.

    Yang J, Yamada A, Shitara K, et al.

    Clinical pharmacokinetics 2025; (64(10)):1465-1476 doi:10.1007/s40262-025-01552-x.

    PMID: 40804604
  16. 16

    Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting.

    Zhou KI, Strickler JH, Chen H

    Journal of hematology & oncology 2024; (17(1)):73 doi:10.1186/s13045-024-01595-w.

    PMID: 39183320
  17. 17

    Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.

    Shah MA, Shitara K, Ajani JA, et al.

    Nature medicine 2023; (29(8)):2133-2141 doi:10.1038/s41591-023-02465-7.

    PMID: 37524953
  18. 18

    Analytical and Clinical Performance of the VENTANA CLDN18 (43-14A) RxDx Assay in Gastric and Gastroesophageal Junction Adenocarcinoma Tissue Samples in SPOTLIGHT and GLOW.

    Stratton SP, Pang L, Pugh J, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2025; (38(12)):100844 doi:10.1016/j.modpat.2025.100844.

    PMID: 40680855
  19. 19

    Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.

    Shitara K, Lordick F, Bang YJ, et al.

    Lancet (London, England) 2023; (401(10389)):1655-1668 doi:10.1016/S0140-6736(23)00620-7.

    PMID: 37068504
  20. 20

    Esophageal cancer: Treatment advances and need for screening.

    Eisner DC

    JAAPA : official journal of the American Academy of Physician Assistants 2024; (37(4)):19-24 doi:10.1097/01.JAA.0001007328.84376.da.

    PMID: 38484297
  21. 21

    Ongoing Controversies in Esophageal Cancer II: Gastrectomy versus Esophagectomy for Siewert Type II Esophageal Adenocarcinoma.

    Devaud N, Carroll P

    Thoracic surgery clinics 2022; (32(4)):553-563 doi:10.1016/j.thorsurg.2022.07.004.

    PMID: 36266040
  22. 22

    Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the Netherlands.

    van Laarhoven H, Verhoeven R, van Berge Henegouwen M, et al.

    EClinicalMedicine 2025; (80()):103067 doi:10.1016/j.eclinm.2024.103067.

    PMID: 39911244

This page explains esophageal adenocarcinoma pathology terminology for educational purposes only. Your pathologist and oncologist are the best sources for interpreting your specific report and biomarker results.

Get notified when new evidence is published on Adenocarcinoma of the oesophagus and oesophagogastric junction.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.